Accenture and Intel Support Neuromorphic Research Project to Develop Robotic Arm for Wheelchair-Bound Pediatric Patients

Accenture and Intel are supporting a neuromorphic computing research project led by the Neuro-Biomorphic Engineering Lab (NBEL) at the Open University of Israel in collaboration with ALYN Hospital, Israel’s leading pediatric and adolescent rehabilitation center. Funded by Accenture through its participation in the Intel Neuromorphic Research Community (INRC), the project is focused on developing and testing a wheelchair-mounted robotic arm to assist patients with performing daily tasks.

Researchers from Accenture Labs and Intel Labs are working with researchers from Open University of Israel to build a wheelchair-mounted robotic arm with adaptive controls, using an algorithm developed by Applied Brain Research (ABR) and Intel’s neuromorphic computing hardware. Wheelchair users will be able to independently control the robotic arm to perform daily tasks that require strength and dexterity of arms and hands, such as drinking from a glass, with 50% fewer errors and a 48% improvement in energy efficiency over traditional control methods. The device will undergo clinical testing and evaluation with patients at ALYN Hospital who rely on electric wheelchairs and have motor impairment of their upper extremities.

Studies suggest that wheelchair-mounted robotic arms provide an increased sense of independence for users and that these assistive tools can reduce the need for caregiver time by up to 41 percent. Today, however, the cost of these devices is incredibly high, making them inaccessible to many people who need them.

“The ability of robotic arms to benefit people today is largely limited due to high cost and excessive power consumption,” said Elishai Ezra Tsur, lead project researcher at the Open University of Israel. “This funding from Accenture, along with additional support from Intel and ABR, is allowing us to explore the implementation of adaptive controls on neuromorphic hardware in an effort to address the need for a collaborative, user-friendly, accurate robotic arm at a significantly reduced cost.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy